Calcitonin Pre-treatment to Improve SPECT-CT Sensitivity

Part of paid clinical trials in Toledo, Ohio.

Sponsor
Joseph Sferra
Study ID
NCT03935984
Phase
PHASE4
Status
Recruiting
Apply to this trial

Conditions

  • Hypercalcemia
  • Primary Hyperparathyroidism

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Calcitonin — DRUG
    Treatment with calcitonin to lower high calcium levels prior to reimaging exam

Study Details

Patients with biochemically confirmed primary hyperparathyroidism and non-localizing SPECT-CT exam within the past year will be included. Subjects will be treated with calcitonin to lower calcium levels immediately prior to reimaging. The goal of this study is to determine whether lowering calcium will improve uptake/retention of sestamibi and improve sensitivity of SPECT-CT to localize parathyroid adenoma.

Key Dates

Start date
May 29, 2019
Status verified
Sep 2024
Primary completion
Jun 1, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
37 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC

Arms

  • Experimental: Treatment Group
    All subjects in this arm will be treated with calcitonin 200IU 2x per day for 2 days, then 1x on day of SPECT-CT imaging

Primary Outcome Measure

Sensitivity of SPECT-CT [ Time Frame: one year ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
ProMedica Toledo HospitalToledoOhio43606
Roberta Redfern, PhD
[email protected]
419-291-7517

Find similar trials in Toledo, OH

By research site
ProMedica Toledo Hospital· Toledo, OH

Related Studies